ITA confirms that a sample provided by Ironman athlete Imogen Carlina Simmonds returned an adverse analytical finding

The ITA confirms that a sample collected from Swiss triathlete Imogen Carlina Simmonds during an out-of-competition anti-doping control on 8 December 2024 has returned an adverse analytical finding for SARMS LGD-4033 (ligandrol) metabolite dihydroxy-LGD-4033, a non-specified substance prohibited at all times.

SARMS LGD-4033 (ligandrol) metabolite Dihydroxy-LGD-4033 is prohibited under the World Anti-Doping Agency’s Prohibited List as a “Other Anabolic Agents” (S1.2).

The athlete has been notified of the case and has requested the B-sample analysis. The B-sample analysis has confirmed the result of the A-sample.

The athlete now has the opportunity to present her explanations for the result.

In accordance with the World Anti-Doping Code and Article 7.4.1 of the IRONMAN Anti-Doping Rules, the athlete is under provisional suspension. The athlete has the right to challenge the provisional suspension and ask for its lifting.

Given that the case is underway, there will be no further comments made.